ArticlePharmaceutics2019
Enhanced Delivery of Imatinib into Vaginal Mucosa via a New Positively Charged Nanocrystal-Loaded in Situ Hydrogel Formulation for Treatment of Cervical Cancer.
Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 40 citations in OpenAlex.
- Formulation, characterization and evaluation of cytotoxic potential for febuxostat loaded chitosomes against cervical cancer cells (Hela cells).Scientific reports · 2026Article
- Synergistic effect of Aloe Vera hydrogels with imatinib for pH-responsive drug release in breast cancer treatment.Drug delivery and translational research · 2026Article
- New insights in nanocrystal technology chemotherapeutic drugs targeting cancer with a translational research paradigm.American journal of translational research · 2025Review
- A Review on Medicinal Approaches of Novel Imatinib Derivatives.Current topics in medicinal chemistry · 2025Review
- Strategies, Challenges, and Prospects of Nanoparticles in Gynecological Malignancies.ACS omega · 2024Review
- Delivery and short-term maternal and fetal safety of vaginally administered PEG-PLGA nanoparticles.Drug delivery and translational research · 2023Article
- Article
- Polydopamine surface-modified hyperbranched polymeric nanoparticles for synergistic chemo/photothermal therapy of oral cancer.Frontiers in bioengineering and biotechnology · 2023Article
- Drug Nanocrystals for Active Tumor-Targeted Drug Delivery.Pharmaceutics · 2022Review
- Emerging Fabrication Strategies of Hydrogels and Its Applications.Gels (Basel, Switzerland) · 2022Review
- Sorafenib Nanomicelles Effectively Shrink Tumors by Vaginal Administration for Preoperative Chemotherapy of Cervical Cancer.Nanomaterials (Basel, Switzerland) · 2021Article
- Sequential Release of Paclitaxel and Imatinib from Core-Shell Microparticles Prepared by Coaxial Electrospray for Vaginal Therapy of Cervical Cancer.International journal of molecular sciences · 2021Article
- Gold nanoparticle biodistribution in pregnant mice following intravenous administration varies with gestational age.Nanomedicine : nanotechnology, biology, and medicine · 2021Article
- Polydopamine-Based "Four-in-One" Versatile Nanoplatforms for Targeted Dual Chemo and Photothermal Synergistic Cancer Therapy.Pharmaceutics · 2019Article
- Transmucosal Absorption Enhancers in the Drug Delivery Field.Pharmaceutics · 2019Article
- A Functional Wound Dressing as a Potential Treatment for Cutaneous Leishmaniasis.Pharmaceutics · 2019Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study was carried out to investigate the potential of cationic functionalization on imatinib nanocrystals to improve the mucoadhesiveness and, thus, delivery to the lesion of cervicovaginal tumors. Amino-group-functionalized imatinib nanocrystals (NC@PDA-NH₂) were prepared with near-spheroid shape, nanoscale size distribution, positive zeta potential, and relatively high drug content with the aid of the polydopamine-coating technique. Efficient interaction between NC@PDA-NH₂ and mucin was proven by mucin adsorption which was related to the positive zeta-potential value of NC@PDA-NH₂ and the change in the size distribution on mixing of NC@PDA-NH₂ and mucin. Cellular uptake, growth inhibition, and apoptosis induction in cervicovaginal cancer-related cells demonstrated the superiority of NC@PDA-NH₂ over unmodified nanocrystals. For practical intravaginal administration, NC@PDA-NH₂ was dispersed in Pluronic F127-based thermosensitive in situ hydrogel, which showed suitable gelation temperature and sustained-release profiles. In comparison with unmodified nanocrystals, NC@PDA-NH₂ exhibited extended residence on ex vivo murine vaginal mucosa, prolonged in vivo intravaginal residence, and enhanced inhibition on the growth of murine orthotopic cervicovaginal model tumors indicated by smaller tumor size, longer median survival time, and more intratumor apoptosis with negligible mucosal toxicity. In conclusion, cationic functionalization endowed NC@PDA-NH₂ significant mucoadhesiveness and, thus, good potential against cervicovaginal cancer via intravaginal administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.